Literature DB >> 24623435

Quantification of deaminase activity-dependent and -independent restriction of HIV-1 replication mediated by APOBEC3F and APOBEC3G through experimental-mathematical investigation.

Tomoko Kobayashi1, Yoshiki Koizumi, Junko S Takeuchi, Naoko Misawa, Yuichi Kimura, Satoru Morita, Kazuyuki Aihara, Yoshio Koyanagi, Shingo Iwami, Kei Sato.   

Abstract

APOBEC3F and APOBEC3G cytidine deaminases potently inhibit human immunodeficiency virus type 1 (HIV-1) replication by enzymatically inserting G-to-A mutations in viral DNA and/or impairing viral reverse transcription independently of their deaminase activity. Through experimental and mathematical investigation, here we quantitatively demonstrate that 99.3% of the antiviral effect of APOBEC3G is dependent on its deaminase activity, whereas 30.2% of the antiviral effect of APOBEC3F is attributed to deaminase-independent ability. This is the first report quantitatively elucidating how APOBEC3F and APOBEC3G differ in their anti-HIV-1 modes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24623435      PMCID: PMC4019142          DOI: 10.1128/JVI.00062-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes.

Authors:  D H Gabuzda; K Lawrence; E Langhoff; E Terwilliger; T Dorfman; W A Haseltine; J Sodroski
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

2.  Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation.

Authors:  Craig Pace; Jean Keller; David Nolan; Ian James; Silvana Gaudieri; Corey Moore; Simon Mallal
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

3.  APOBEC3G DNA deaminase acts processively 3' --> 5' on single-stranded DNA.

Authors:  Linda Chelico; Phuong Pham; Peter Calabrese; Myron F Goodman
Journal:  Nat Struct Mol Biol       Date:  2006-04-23       Impact factor: 15.369

4.  Remarkable lethal G-to-A mutations in vif-proficient HIV-1 provirus by individual APOBEC3 proteins in humanized mice.

Authors:  Kei Sato; Taisuke Izumi; Naoko Misawa; Tomoko Kobayashi; Yoshiki Yamashita; Masahide Ohmichi; Mamoru Ito; Akifumi Takaori-Kondo; Yoshio Koyanagi
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

5.  Modulation of human immunodeficiency virus type 1 infectivity through incorporation of tetraspanin proteins.

Authors:  Kei Sato; Jun Aoki; Naoko Misawa; Eriko Daikoku; Kouichi Sano; Yuetsu Tanaka; Yoshio Koyanagi
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

6.  APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo.

Authors:  Mark T Liddament; William L Brown; April J Schumacher; Reuben S Harris
Journal:  Curr Biol       Date:  2004-08-10       Impact factor: 10.834

7.  Analysis of the percentage of human immunodeficiency virus type 1 sequences that are hypermutated and markers of disease progression in a longitudinal cohort, including one individual with a partially defective Vif.

Authors:  Anne Piantadosi; Daryl Humes; Bhavna Chohan; R Scott McClelland; Julie Overbaugh
Journal:  J Virol       Date:  2009-06-03       Impact factor: 5.103

8.  Crystal structure of the DNA cytosine deaminase APOBEC3F: the catalytically active and HIV-1 Vif-binding domain.

Authors:  Markus-Frederik Bohn; Shivender M D Shandilya; John S Albin; Takahide Kouno; Brett D Anderson; Rebecca M McDougle; Michael A Carpenter; Anurag Rathore; Leah Evans; Ahkillah N Davis; Jingying Zhang; Yongjian Lu; Mohan Somasundaran; Hiroshi Matsuo; Reuben S Harris; Celia A Schiffer
Journal:  Structure       Date:  2013-05-16       Impact factor: 5.006

Review 9.  Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics.

Authors:  John S Albin; Reuben S Harris
Journal:  Expert Rev Mol Med       Date:  2010-01-22       Impact factor: 5.600

10.  Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates.

Authors:  Véronique Zennou; Paul D Bieniasz
Journal:  Virology       Date:  2006-02-07       Impact factor: 3.616

View more
  20 in total

Review 1.  APOBECs and virus restriction.

Authors:  Reuben S Harris; Jaquelin P Dudley
Journal:  Virology       Date:  2015-03-26       Impact factor: 3.616

2.  Long-term passage of Vif-null HIV-1 in CD4+ T cells expressing sub-lethal levels of APOBEC proteins fails to develop APOBEC resistance.

Authors:  Eri Miyagi; Sandra Kao; Miyoshi Fumitaka; Alicia Buckler-White; Ron Plishka; Klaus Strebel
Journal:  Virology       Date:  2017-01-25       Impact factor: 3.616

3.  Vif determines the requirement for CBF-β in APOBEC3 degradation.

Authors:  Rokusuke Yoshikawa; Junko S Takeuchi; Eri Yamada; Yusuke Nakano; Fengrong Ren; Hiroshi Tanaka; Carsten Münk; Reuben S Harris; Takayuki Miyazawa; Yoshio Koyanagi; Kei Sato
Journal:  J Gen Virol       Date:  2014-12-16       Impact factor: 3.891

4.  Multifaceted HIV-1 Vif interactions with human E3 ubiquitin ligase and APOBEC3s.

Authors:  Yingxia Hu; Kirsten M Knecht; Qi Shen; Yong Xiong
Journal:  FEBS J       Date:  2020-09-21       Impact factor: 5.542

5.  The Role of RNA in HIV-1 Vif-Mediated Degradation of APOBEC3H.

Authors:  Jiayi Wang; Jordan T Becker; Ke Shi; Kate V Lauer; Daniel J Salamango; Hideki Aihara; Nadine M Shaban; Reuben S Harris
Journal:  J Mol Biol       Date:  2019-10-16       Impact factor: 5.469

6.  Pandemic HIV-1 Vpu overcomes intrinsic herd immunity mediated by tetherin.

Authors:  Shingo Iwami; Kei Sato; Satoru Morita; Hisashi Inaba; Tomoko Kobayashi; Junko S Takeuchi; Yuichi Kimura; Naoko Misawa; Fengrong Ren; Yoh Iwasa; Kazuyuki Aihara; Yoshio Koyanagi
Journal:  Sci Rep       Date:  2015-07-17       Impact factor: 4.379

Review 7.  APOBEC3 Interference during Replication of Viral Genomes.

Authors:  Luc Willems; Nicolas Albert Gillet
Journal:  Viruses       Date:  2015-06-11       Impact factor: 5.048

Review 8.  Suppression of APOBEC3-mediated restriction of HIV-1 by Vif.

Authors:  Yuqing Feng; Tayyba T Baig; Robin P Love; Linda Chelico
Journal:  Front Microbiol       Date:  2014-08-26       Impact factor: 5.640

9.  APOBEC3D and APOBEC3F potently promote HIV-1 diversification and evolution in humanized mouse model.

Authors:  Kei Sato; Junko S Takeuchi; Naoko Misawa; Taisuke Izumi; Tomoko Kobayashi; Yuichi Kimura; Shingo Iwami; Akifumi Takaori-Kondo; Wei-Shau Hu; Kazuyuki Aihara; Mamoru Ito; Dong Sung An; Vinay K Pathak; Yoshio Koyanagi
Journal:  PLoS Pathog       Date:  2014-10-16       Impact factor: 6.823

10.  Experimental evaluation of the zoonotic infection potency of simian retrovirus type 4 using humanized mouse model.

Authors:  Kei Sato; Tomoko Kobayashi; Naoko Misawa; Rokusuke Yoshikawa; Junko S Takeuchi; Tomoyuki Miura; Munehiro Okamoto; Jun-ichirou Yasunaga; Masao Matsuoka; Mamoru Ito; Takayuki Miyazawa; Yoshio Koyanagi
Journal:  Sci Rep       Date:  2015-09-14       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.